| iPSC-Derived Astrocytes | |
|---|---|
| Lineage | Stem Cell > iPSC > Astrocyte |
| Markers | GFAP, S100β, ALDH1L1, AQP4, EAAT1, EAAT2 |
| Brain Regions | In Vitro |
| Disease Relevance | Alzheimer's Disease, Parkinson's Disease, ALS, Astrocytosis |
| Protocol | Directed Differentiation (30-90 days) |
Ipsc Derived Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
iPSC-Derived Astrocytes are specialized glial cells generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols that recapitulate astrogliogenesis during central nervous system development.[1] These cells express characteristic astrocytic markers including GFAP (glial fibrillary acidic protein), S100β, ALDH1L1, and the water channel AQP4, defining their identity as authentic astrocytes.[2]
iPSC-derived astrocytes provide physiologically relevant in vitro models for studying neurodevelopment, neuroinflammation, and neurodegenerative diseases.[3] These cells are particularly valuable for modeling Alzheimer's disease, Parkinson's disease, and ALS, where astrocyte dysfunction plays a critical role in disease pathogenesis.[4]
The generation of astrocytes from iPSCs typically follows a directed differentiation approach:
| Marker | Type | Function |
|---|---|---|
| GFAP | Intermediate Filament | Astrocyte identity, reactivity |
| S100β | Calcium-binding Protein | Astrocyte maturation |
| ALDH1L1 | Enzyme | Folate metabolism |
| AQP4 | Water Channel | Water homeostasis |
| EAAT1 (GLAST) | Transporter | Glutamate uptake |
| EAAT2 (GLT1) | Transporter | Glutamate uptake |
| Connexin 43 | Gap Junction | Astrocyte coupling |
iPSC-derived astrocytes from AD patients exhibit:
| Differentiation Method | Maturation Time | Marker Expression | Function |
|---|---|---|---|
| Spontaneous differentiation | 60-90 days | Variable | Research |
| CNTF/BMP patterning | 30-60 days | Robust | Disease modeling |
| Defined medium | 40-70 days | Moderate | Standardization |
Krencik et al. 2011 - Directed differentiation of functional astrocytes from human pluripotent stem cells. 2011. ↩︎
Tcw et al. 2017 - Human iPSC-derived astrocytes: disease modeling and therapeutic applications. 2017. ↩︎
Santos et al. 2023 - Astrocyte disease modeling with iPSCs. 2023. ↩︎
G、商业 et al. 2024 - iPSC astrocytes in neurodegeneration research. 2024. ↩︎
Blacher et al. 2015 - Alzheimer's disease astrocyte phenotypes. 2015. ↩︎